Market Overview

UPDATE: Sterne Agee Initiates Coverage On Cyberonics

Share:
Related CYBX
Cyberonics Posts Upbeat Q4 Profit, But Revenue Misses Estimates
Earnings Scheduled For June 4, 2015
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

In a report released Monday, Sterne Agee analyst Greg Chodaczek initiates coverage on Cyberonics (NASDAQ: CYBX) with a Buy rating and a $65 price target.

Chodaczek believes Cyberonics potential is in Epilepsy being the fourth most common neurological disorder in the country. In the United States alone, approximately 2.2 million people are diagnosed with epilepsy and about 400,000 are believed to require neuromodulation therapy. Chodaczek projects refractory epilepsy market penetration to be 10 percent, presenting massive opportunity for Cyberonics.

Cyberonics reports it owns or licenses about 173 U.S. patents and 299 pending U.S. patent applications.

Product Pipeline

Over the past three fiscal years, Cyberonics balance sheet consists of $120 million on clinical and regulatory actions to improve its VNS franchise. Cyberonics Model 106 (AspireSR) is speculated by Sterne Agee to be the first product in Cyberonics pipeline to receive FDA approval.

Shares of Cyberonics are trading at $59.14, up 0.25 percent.

Latest Ratings for CYBX

DateFirmActionFromTo
Jun 2015JefferiesMaintainsHold
Jun 2015Canaccord GenuityMaintainsHold
Mar 2015JefferiesDowngradesBuyHold

View More Analyst Ratings for CYBX
View the Latest Analyst Ratings

Posted-In: Greg Chodaczek. Sterne AgeeAnalyst Color Price Target Initiation Analyst Ratings

 

Related Articles (CYBX)

Get Benzinga's Newsletters